Publications by authors named "C Morosi"
Background: Risk-stratification of patients with retroperitoneal sarcomas (RPS) relies on validated nomograms, such as Sarculator. This retrospective study investigated whether radiomic features extracted from computed tomography (CT) imaging could i) enhance the performance of Sarculator and ii) identify G3 dedifferentiated liposarcoma (DDLPS) or leiomyosarcoma (LMS), which are currently consider in a randomized clinical trial testing neoadjuvant chemotherapy.
Methods: Patients with primary localized RPS treated with curative-intent surgery (2011-2015) and available pre-operative CT imaging were included.
Article Synopsis
- The study investigates abdominal venous leiomyosarcoma (AV-LMS), focusing on its origins from veins associated with the sex-hormone drainage pathway (SHDP).
- A retrospective analysis of imaging from 155 patients with confirmed non-uterine abdominal/pelvic LMS revealed that more than half of the tumors originated from venous structures, particularly those linked to the SHDP, including adrenal and ovarian veins.
- Key findings indicate that tumors from the SHDP are prevalent and may lead to a lower risk of distant metastases at diagnosis, with tumor size and SHDP origin being critical factors in predicting metastasis risk.
Article Synopsis
- Pleomorphic liposarcoma (PLPS) is a rare cancer, and this study focused on the surgical outcomes and treatment strategies for patients with non-metastatic PLPS from 2002 to 2019.* -
- The research involved analyzing data from 44 verified cases, finding that 75% of patients survived for at least five years, with larger tumors linked to worse survival outcomes and higher risks of disease-specific death.* -
- The study concluded that aggressive surgery combined with radiation therapy leads to good local control, while smaller Grade 2 tumors might be effectively treated with surgery alone.*
Article Synopsis
- Epithelioid hemangioendothelioma (EHE) is difficult to treat with traditional chemotherapy, prompting researchers to explore new therapies such as sirolimus and identify biomarkers for tumor aggressiveness.
- Scientists created a patient-derived xenograft (PDX) model from an advanced EHE patient to test sirolimus and to study serum levels of Growth/Differentiation Factor 15 (GDF-15) as a potential biomarker.
- The results indicated sirolimus was more effective than doxorubicin in reducing tumor growth and GDF-15 levels, establishing GDF-15 as a promising biomarker for EHE aggressiveness and potentially indicating the effectiveness of sirolimus in patients.
Objective: Evaluate the feasibility and outcomes of the implementation of a routinely prehabilitation nutritional program (PNP) in retroperitoneal sarcoma (RPS) patients.
Summary Background Data: Rate of preoperative malnutrition is scarcely evaluated in RPS patients and the efficacy of a PNP in detecting and reverting malnutrition has not been studied.
Methods: Prospective study in a high-volume reference center for RPS; adult patients with primary or persistent RPS deemed surgically resectable were enrolled in a PNP.